Related Experiment Video

Updated: Dec 2, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.9K

Past, Present and Future of Oncolytic Reovirus

Louise Müller1, Robert Berkeley1, Tyler Barr1

  • 1Leeds Institute of Medical Research (LIMR), University of Leeds, Leeds LS9 7TF, UK.

Cancers
|November 4, 2020
PubMed

Insights

Oncolytic reovirus (pelareorep) shows potential in cancer treatment by directly killing tumor cells and boosting anti-tumor immunity. Combination therapies are key to maximizing its effectiveness against various cancers.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Oncolytic virotherapy (OVT) is a growing field, highlighted by the FDA approval of talimogene Laherparepvec (T-VEC).
  • Oncolytic viruses (OVs) function by inducing direct tumor cell lysis and stimulating anti-tumor immune responses.
  • Tumor microenvironment (TME) complexity necessitates tailored approaches for OV efficacy across different cancers.

Purpose of the Study:

  • To provide an unbiased review of oncolytic reovirus (pelareorep).
  • To detail the molecular and cellular mechanisms of reovirus-induced oncolysis and anti-tumor immunity.
  • To discuss the clinical trajectory and combination strategies for reovirus in cancer therapy.

Main Methods:

  • Review of pre-clinical efficacy data for oncolytic reovirus.
  • Analysis of molecular and cellular mechanisms of reovirus action.
  • Evaluation of clinical trial data and combination therapeutic approaches.

Main Results:

  • Oncolytic reovirus demonstrates direct tumor cell killing and immune stimulation.
  • Efficacy of reovirus is influenced by TME and tumor type.
  • Combination strategies show promise for enhancing reovirus therapeutic potential.

Conclusions:

  • Oncolytic reovirus (pelareorep) is a promising therapeutic agent with dual mechanisms of action.
  • Tailored combination strategies are essential to overcome limitations and maximize reovirus efficacy.
  • Further research is needed to fully harness the potential of reovirus in cancer treatment.
Keywords:
immunotherapyoncolytic virusreovirus

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

9.7K

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
718
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.8K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.7K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.3K
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
337
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K